She is 43 years old when the diagnosis finally arrives. Looking back, the trail is longer than anyone had recognized. Fatigue that never fully resolved after a demanding job five years earlier. Joint pain that came and went without a clear pattern. Sleep that stopped being restorative somewhere in her late 30s. A history of recurrent infections that previous practitioners attributed to stress. Each symptom managed in isolation, each investigation returning results that were abnormal enough to concern her but insufficient to explain her clinical picture. Then the antinuclear antibody panel, the complement levels, the renal involvement — and suddenly the pieces coalesce into a diagnosis of systemic lupus erythematosus (SLE).
For the clinician managing her now, the more important question is not what she has. It is why her immune system crossed the threshold it did, when it did — and why another patient with a similar genetic background and comparable environmental exposures never will.
That question — why some patients develop autoimmune disease while others do not, and why treatment response varies so dramatically once disease is established — is the central clinical problem that Systems Homeostasis addresses. The framework positions treatment response variability not as biological noise but as a predictable consequence of differences in signal environment: the upstream physiological state a patient carries into any pathological event. In autoimmune disease, that signal environment is not incidental to disease development. It is, as emerging research now suggests, the determinant of whether a ubiquitous pathogen becomes a disease driver.
The Central Question for Clinicians: Why This Patient, Now?
In late 2025, a Stanford University research team published findings in Science Translational Medicine that provided the first mechanistic explanation for one of immunology’s most persistent associations: the link between Epstein-Barr Virus (EBV) and SLE. EBV infects more than 94% of the global population; however, the vast majority of those individuals never develop lupus. The Stanford study demonstrated that in SLE patients, EBV infects and reprograms a subset of autoreactive B cells — cells already primed to respond to self-antigens — converting them into pathogenic antigen-presenting cells capable of activating broad networks of autoreactive immune responses. In lupus patients, approximately 1 in 400 B cells harbor latent EBV, compared to fewer than 1 in 10,000 in healthy individuals.
The finding is significant. It provides a mechanistic bridge between viral infection and autoimmune disease initiation that had previously been associative rather than explanatory. But it immediately raises the question that conventional immunology is structurally disinclined to ask: why does EBV behave differently in some patients than others? Why does a virus present in nearly every adult on earth drive autoimmunity in a fraction of them? The answer does not lie in the virus. It lies in the signal environment the host presents to it.
Key Mechanistic Finding: EBV Reprograms Autoreactive B Cells
EBV does not replicate freely in healthy individuals. It persists in a latent state within memory B cells, held in check by continuous immune surveillance — specifically by CD8+ cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells that patrol for and suppress Epstein-Barr Nuclear Antigen (EBNA)–expressing B cells. This surveillance architecture is not passive. It is metabolically demanding, cytokine-dependent, and exquisitely sensitive to the hormonal environment in which it operates.
Chronic psychological and physiological stress, mediated through sustained hypothalamic-pituitary-adrenal (HPA) axis activation, systematically degrades this surveillance architecture through several converging mechanisms. Elevated cortisol suppresses interleukin-12 (IL-12) and interferon-gamma (IFN-γ), the two cytokines most critical for CTL activation and maintenance. It downregulates Major Histocompatibility Complex (MHC) class I expression on virally infected cells, reducing the efficiency with which CTLs can identify and eliminate them. It promotes T cell apoptosis, contracting the CTL pool available for ongoing surveillance. And it suppresses NK cell activity — the innate immune system’s first-line response to EBV reactivation before adaptive immunity can be fully mobilized.
The result is not viral reactivation caused by cortisol directly. It is viral containment failure — the progressive dismantling of the surveillance infrastructure that keeps latent EBV behaviorally inert. EBNA2 expression, the molecular event that initiates B cell reprogramming, becomes possible when the immune architecture that normally suppresses it has been chronically degraded.
DHEA, which declines progressively as cortisol dominance is sustained — through zona reticularis atrophy and central suppression of the hypothalamic-pituitary-gonadal axis — exerts Th1-supportive and antiviral effects that partially offset cortisol’s immunosuppressive bias. Its loss compounds the surveillance deficit rather than representing a separate phenomenon. The stress axis is not pushing immune function in one direction. Rather, it is simultaneously removing the brake.
The 43-year-old patient in the opening scenario did not develop lupus because she was unlucky. She developed it because her signal environment — shaped by years of HPA dysregulation, progressive erosion of viral surveillance capacity, and enteric immune dysfunction operating beneath the threshold of clinical recognition — created the conditions under which a latent pathogen present in nearly every adult could cross from containment to consequence.
Measurable Clinical Signals: Diurnal Cortisol and DHEA Profiles
This is not a theoretical construct. The HPA dysregulation state described above produces characteristic patterns on functional laboratory assessment that are accessible to any clinician willing to look upstream of symptoms.
The Fluids-IQ SHP panel (a comprehensive 24-hour salivary hormone profile measuring cortisol across four time points and DHEA at morning baseline) consistently reveals dysregulated diurnal cortisol patterns in patients with autoimmune conditions and complex chronic illness. The patterns most clinically relevant to the EBV surveillance failure argument are not necessarily dramatically elevated cortisol values. More commonly, the panel reveals a blunted diurnal decline — cortisol remaining inappropriately elevated through the afternoon and evening rather than following its normal steep descent. Or, the panel shows a flattened curve consistent with chronic HPA exhaustion, where low-grade but persistent cortisol exposure maintains Th1 suppression without appearing acutely elevated on standard serum testing. An inverted pattern, with low morning and elevated evening cortisol, represents advanced circadian disruption and is particularly significant given that CTL and NK surveillance activity follows its own circadian rhythm, peaking during sleep and early morning hours.
An additional upstream marker warrants clinical attention, though its application in this context remains at the hypothesis stage. Midday salivary melatonin is frequently misunderstood as a sleep marker — a readout of pineal gland function governed by the light-dark cycle. The more clinically significant melatonin pool is enteric in origin. The gastrointestinal tract produces melatonin in quantities that dwarf pineal output, operating independently of circadian light cues and serving as a primary regulator of local immune function, gut barrier integrity, and anti-inflammatory signaling within the enteric immune environment.
Circadian Inversion and Its Implications
Depressed midday melatonin in this context is not a statement about sleep architecture. It is a readout of enteric immune competence — an indicator that the GI immune environment is failing to maintain its regulatory and anti-inflammatory signaling output. This connects directly to the functional GI assessment picture. Tight junction compromise, secretory IgA suppression, and dysbiotic patterns do not occur in isolation from the enteric melatonin system — they occur within the same tissue compartment responsible for the majority of the body’s melatonin production. GI immune dysfunction and depressed enteric melatonin are not parallel findings. They are aspects of the same upstream deterioration.
Whether depressed enteric melatonin can serve as an early systemic autoimmune risk indicator — capturing GI immune dysfunction before it has fully expressed at the clinical level — remains to be formally established. The parallel with functional GI assessment is instructive. Panels identifying tight junction compromise, secretory IgA suppression, and dysbiotic patterns can detect GI architecture deterioration years before frank inflammatory bowel disease or Crohn’s disease meets diagnostic criteria. The mechanistic logic is consistent: the signal environment deteriorates before the clinical threshold is crossed, and functional assessment can identify that deterioration if clinicians know where to look.
The Signal Environment as Disease Determinant
The 43-year-old patient in the opening scenario did not develop lupus because she was unlucky. She developed it because her signal environment — shaped by years of HPA dysregulation, progressive erosion of viral surveillance capacity, and enteric immune dysfunction operating beneath the threshold of clinical recognition — created the conditions under which a latent pathogen present in nearly every adult could cross from containment to consequence.
The Stanford findings confirm the mechanism. They do not explain the variability. That variability is explained by the upstream signal environment each patient presents at the moment of pathological transition — which is precisely what Systems Homeostasis is designed to assess and address.
In Part 2, we examine what happens after EBV successfully reprograms autoreactive B cells into pathogenic antigen-presenting cells — the interferon-I amplification loop, the homeostatic circuit breakers that determine whether the cascade is contained or escalates to systemic autoimmune disease, and why the same stress axis state that permitted viral reactivation simultaneously degrades the patient’s capacity to limit the damage.
References
Younis S, Moutusy SI, Rasouli S, et al. Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus. Sci Transl Med. 2025;17(824):eady0210. doi:10.1126/scitranslmed.ady0210
Jog NR, James JA. Epstein Barr virus and autoimmune responses in systemic lupus erythematosus. Front Immunol. 2021;11:623944. doi:10.3389/fimmu.2020.623944
Wheatley LM, Peden DB, Togias A. Physiology, cortisol. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538239/
Dhabhar FS. Effects of stress on immune function: the good, the bad, and the beautiful. Immunol Res. 2014;58(2-3):193–210. doi:10.1007/s12026-014-8517-0
Morawiec N, Adamczyk B, Spyra A, et al. The role of Epstein-Barr virus in the pathogenesis of autoimmune diseases. Medicina. 2025;61(7):1148. doi:10.3390/medicina61071148
Kvetnoy IM, Ingel IE, Kvetnaia TV, et al. Gastrointestinal melatonin: cellular identification and biological role. Neuroendocrinol Lett. 2002;23(2):121–132. PMID:12011773
Babaei P, Moqaddami A, Damirchi A. The melatonin-microbiome axis: a new frontier in gut health for the immunomodulatory, antioxidant and anti-inflammatory properties. Inflammopharmacology. 2025. doi:10.1007/s10787-025-02005-4
Zhu S, et al. Melatonin as the missing link between sleep deprivation and immune dysregulation: a narrative review. PMC. 2025. PMCID:PMC12296019
